Neratinib for HER2-positive breast cancer with an overlooked option

• Main Authors: Liting Guo (Author), Weiwei Shao (Author), Chenfei Zhou (Author), Hui Yang (Author), Liu Yang (Author), Qu Cai (Author), Junqing Wang (Author), Yan Shi (Author), Lei Huang (Author), Jun Zhang (Author)
• Format: Book
• Published: BMC, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Positive human epidermal growth factor receptor 2 (HER2) expression is associated with an increased risk of metastases especially those to the brain in patients with advanced breast cancer (BC). Neratinib as a tyrosine kinase inhibitor can prevent the transduction of HER1, HER2 and HER4 sig...